Claris Bio

Drug Discovery · Jersey City, NJ · Founded 2018 · Privately Held (backing)

Developer of a topical formulation technology designed to treat orphan ophthalmic disorders. Claris Bio is based in Jersey City, NJ and was founded in 2018. It was valued at $163 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $54.5 million Series A in Jan 2024.

PMV mark · valuation
$163.4M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$153.6M
Last round
Later Stage VC (Series A)
Jan 2024

Who backs Claris Bio?

5 investors
InvestorType
RA Capital ManagementAsset manager
Novo HoldingsOther
Catalio Capital ManagementVenture capital
Janus Henderson Investors—
Mass General Brigham Ventures—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Claris Bio investors

5 investors are on record for Claris Bio, including RA Capital Management, Novo Holdings, Catalio Capital Management and Janus Henderson Investors. The Series A in Jan 2024 drew 3 investors.

Free account
More of Claris Bio with a free account
  • ·Watch Claris Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 5 firms already write checks for companies like Claris Bio in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View